Oculis Holding AG - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OCS Nasdaq 2830 oculis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Oculis Holding AG

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - Jun 11th, 2026 2:00 am
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - Jun 9th, 2026 2:00 am
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - Jun 8th, 2026 1:25 pm
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - Jun 8th, 2026 5:16 am
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals - May 31st, 2026 3:03 pm
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target - May 29th, 2026 2:18 pm
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint - May 29th, 2026 1:46 pm
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema - May 29th, 2026 1:06 pm
Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls - May 21st, 2026 7:40 am
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - May 15th, 2026 2:05 pm
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors - May 14th, 2026 2:05 pm
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates - May 11th, 2026 4:05 pm
Oculis Reports Q1 2026 Financial Results and Provides Company Update - May 11th, 2026 2:07 pm
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains - May 10th, 2026 11:09 pm
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 6:50 am
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial - May 7th, 2026 3:00 am
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates - May 6th, 2026 6:25 am
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - May 5th, 2026 2:00 am
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - May 1st, 2026 2:00 am
Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? - Apr 29th, 2026 12:07 pm